Abstract
Mental disorders are a significant cause of morbidity and mortality in pregnant women. Although not thoroughly studied in developing country settings, the use of pharmacotherapy in pregnancy poses a major public health challenge that is certain to be prominent in populations skewed towards reproductive age. The standard of care calls for stringent efforts to control perinatal mental disorders as essential for favorable pregnancy outcomes for both mother and neonate. Psychotropic medications have been shown effective in control of relevant conditions, and presently, with the exception of some antiepileptic drugs, have not been associated with significant teratogenic risk. In all clinical situations, the benefits of maternal, fetal, and neonatal well-being should be weighed on an individual basis against potential teratogenesis. Thoughtful management of pregnant patients suffering from mental health disorders and prescription of monotherapy, if clinically suitable, will increase the odds of favorable maternal/neonatal outcomes, including future child well-being.
Keywords
- Autism Spectrum Disorder
- Autism Spectrum Disorder
- Psychotropic Medication
- Prenatal Exposure
- Postpartum Depression
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
The World Bank. World development indicators: population dynamics. 2014. http://wdi.worldbank.org/table/2.1. Accessed 06 Oct 2014.
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.
The World Health Organization. Mental health, poverty, and development. 2009. http://www.who.int/nmh/publications/discussion_paper_en.pdf. Accessed 06 Oct 2014.
Andersson L, Sundstrom-Poromaa I, Bixo M, Wulff M, Bondestam K, åStröm M. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol. 2003;189:148–54.
Vesga-López O, Blanco C, Keyes K, Olfson M, Grant BF, Hasin DS. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry. 2008;65:805–15.
Larson WJ. Essentials of human embryology. New York: Churchill-Livingstone; 1998.
Ratnapalan S, Bentur Y, Koren G. Doctor, will that x-ray harm my unborn child? Can Med Assoc J. 2008;179:1293–6.
Moran B, Yano H, Al Zahir N, Farquharson M. Conflicting priorities in surgical intervention for cancer in pregnancy. Lancet Oncol. 2007;8:536–44.
Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS. Increasing off-label use of antipsychotic medication in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2001;20:177–84.
Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry. 2007;164:1214–20.
Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Shapiro S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol. 1977;128:486–8.
Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28:279–88.
Habermann F, Fritzsche J, Fuhlbrück F, Wacker E, Allignol A, Weber-Schoendorfer C, et al. Atypical antipsychotic drugs and pregnancy outcome. J Clin Psychopharmacol. 2013;33:453–62.
Diav-Citrin O, Shechtman S, Ornoy S, Arnon J, Schaefer C, Garbio H, et al. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry. 2005;66:317–22.
Sadowski A, Todorow M, Brojeni PY, Gideon K, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. Br Med J Open. 2013;3:e003062.
Lin H, Chen I, Chen Y, Lee H, Wu F. Maternal schizophrenia and pregnancy outcome: does the use of antipsychotics make a difference? Schizophr Res. 2010;116:55–60.
Bodén R, Lundgren M, Brandt L, Reutfors J, Kieler H. Antipsychotics during pregnancy: relation to fetal and maternal metabolic effects. Arch Gen Psychiatry. 2012;69:715–21.
Newham JJ, Thomas SH, MacRitchie K, McElhatton PR, McAllister-Williams RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008;192:333–7.
Bellet F, Beyens MN, Bernard N, Beghin D, Elefant E, Vial T. Pregnancy outcome in women exposed to aripiprazole during the embryonic period: a prospective multicentric cohort. Fundam Clin Pharmacol. 2013;27:43. doi:10.1111/fcp.12025.
Johnson KC, LaPrairie JL, Brennan PA, Stowe ZN, Newport DJ. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry. 2012;69:787–94.
Peng M, Gao K, Ding Y. Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants: a case-controlled, prospective study. Psychopharmacology. 2013;228:577–84.
Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. Br Med J. 2001;323:257–60.
Halbreich U. Prevalence of mood symptoms and depressions during pregnancy: implications for clinical practice and research. CNS Spectr. 2004;9:177–84.
Meltzer-Brody S. New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum. Dialogues Clin Neurosci. 2011;13:89–100.
Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 2012;169:1165–74.
Wisborg K, Barklin A, Hedegaard M, Henriksen TB. Psychological stress during pregnancy and stillbirth: prospective study. BJOG. 2008;115:882–5.
Einarson A, Selby P, Koren G. Abrupt discontinuation of psychotropic drugs during pregnancy: fear of teratogenic risk and impact of counseling. J Psychiatry Neurosci. 2001;26:44–8.
Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006;295:499–507.
Ferguson J. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry. 2001;3:22–7.
McElhatton PR, Garbis HM, Elefant E, Vial T, Bellemin B, Mastroiacovo P, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol. 1996;10:285–94.
Nulman I, Rovet J, Stewart D, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336:258–62.
Nulman I, Rovet J, Stewart D, Wolpin J, Pace-Asciak P, Shuhaiber S, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159:1889–95.
Shearer WT, Schreiner RL, Marshall RE. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr. 1972;81:570–2.
Ross LE, Grigoriadis S, Mamisashvili L, VonderPorten EH, Roerecke M, Rehm J, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. 2013;70:436–43.
Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010–5.
Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. Br J Obs Gyn. 2008;115:283–9.
US Food and Drug Administration. FDA Medwatch drug alert on Effexor and SSRIs. www.fda.gov/medwatch/safety/2004/safety04.htm#effexor. Accessed 17 Oct 2014.
Health Canada. Health Canada advises of potential adverse effects of SSRIs and other anti-depressants on newborns. (Identification number RA-11000190). 2004. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2004/13187a-eng.php. Accessed 17 Oct 2014.
Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354:579–87.
Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008;17:801–6.
Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Psychiatry. 2011;169:134–40.
Grigoriadis S, VonderPorten EH, Mamisashvili L, Tomlinson G, Dennis C-L, Koren G, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. Br Med J. 2014;348:f6932.
Kieler H, Artama M, Engeland A, Ericsson Ö, Ericsson Ö, Furu K, Gissler M, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. Br Med J. 2011;344:d8012.
Occhiogrosso M, Omran SS, Altemus M. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am J Psychiatry. 2012;169:134–40.
Kallen B, Olausson PO. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol. 2006;21:221–2.
Malm H, Artama M, Gissler M, Ritvanen A, et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol. 2011;118:111–20.
Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry. 2008;165:749–52.
Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. Br Med J. 2009;339:b3569.
Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;4:402–8.
Mortensen JT, Olsen J, Larsen H, Bendsen J, Obel C, Sørensen HT. Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur J Epidemiol. 2003;18:769–71.
Oberlander T, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE. Externalizing and attentional behaviours in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med. 2007;161:22–9.
Oberlander TF, Papsdorf M, Brain UM, Misri S, Ross C, Grunnau RE. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch Pediatr Adolesc Med. 2010;164:444–51.
Hviid A, Melbye M, Pasternak B. Use of selective serotonin reuptake inhibitors during pregnancy and risk of autism. N Engl J Med. 2013;369:2406–15.
Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case–control study. Br Med J. 2013;346:f2059.
Patrick RP, Ames BN. Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. FASEB J. 2014;28:2398–413.
Haw C, Stubbs J. A survey of the off-label use of mood stabilizers in a large psychiatric hospital. J Psychopharmacol. 2005;19:402–7.
Ettinger AB, Argoff CE. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics. 2007;4:75–83.
Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology. 2005;64:961–5.
Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA. 2011;305:1996–2002.
Christensen J, Grønborg TK, Sørensen MJ, Schendel D, Parner ET, Pedersen LH, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309:1696–703.
Adab N, Kini U, Vinten J, Ayres J, Baker G, Clayton-Smith J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004;75:1575–83.
Meador KJ, Baker GA, Browning N, Clayton-Smith J, Combs-Cantrell DT, Cohen M, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009;360:1597–605.
US Food and Drug Administration. FDA Drug Safety Communication. Children born to mothers who took Valproate products while pregnant may have impaired cognitive development. 2011. http://www.fda.gov/Drugs/DrugSafety/ucm261543.htm. Accessed 17 Oct 2014.
Schou M. What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand. 1976;54:193–7.
Pinelli JM, Symington AJ, Cunningham KA, Paes BA. Case report and review of the perinatal implications of maternal lithium use. Am J Obs Gyn. 2002;187:245–9.
Diav-Citrin O, Shechtman S, Tahover E, Finkel-Pekarsky V, Arnon J, Kennedy D, et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry. 2014;171:785–94.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Nulman, I., Terrana, P.N., Lutwak, M., Pearlston, M. (2015). Psychotropic Medications in Pregnancy. In: MacLeod, S., Hill, S., Koren, G., Rane, A. (eds) Optimizing Treatment for Children in the Developing World. Adis, Cham. https://doi.org/10.1007/978-3-319-15750-4_25
Download citation
DOI: https://doi.org/10.1007/978-3-319-15750-4_25
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-15749-8
Online ISBN: 978-3-319-15750-4
eBook Packages: MedicineMedicine (R0)